Search results
Results from the WOW.Com Content Network
The coagulation cascade is a normal physiological process to prevent significant blood loss or hemorrhage following vascular injury. Unfortunately, there are times when a blood clot forms when it is not needed. For instance, some high-risk conditions, such as prolonged immobilization, surgery, or cancer, can increase the risk of developing a ...
Bleeding, hemorrhage, haemorrhage or blood loss is blood escaping from the circulatory system from damaged blood vessels. [1] Bleeding can occur internally , or externally either through a natural opening such as the mouth , nose , ear , urethra , vagina or anus , or through a puncture in the skin .
Warfarin should not be given to people with heparin-induced thrombocytopenia until platelet count has improved or normalised. [39] Warfarin is usually best avoided in people with protein C or protein S deficiency, as these thrombophilic conditions increase the risk of skin necrosis, which is a rare but serious side effect associated with ...
Warfarin-induced skin necrosis is a condition in which skin and subcutaneous tissue necrosis (tissue death) occurs due to acquired protein C deficiency following treatment with anti-vitamin K anticoagulants (4-hydroxycoumarins, such as warfarin). [1] Warfarin necrosis is a rare but severe complication of treatment with warfarin or related ...
Other uses include a deficiency of one of the included clotting factors, either congenital or due to liver disease, and hemophilia. [18] Several guidelines, including those from the American College of Chest Physicians, recommend prothrombin complex concentrate for warfarin reversal in people with serious bleeding. [19] [20] [21] [22]
An anticoagulant, commonly known as a blood thinner, is a chemical substance that prevents or reduces the coagulation of blood, prolonging the clotting time. [1] Some occur naturally in blood-eating animals, such as leeches and mosquitoes, which help keep the bite area unclotted long enough for the animal to obtain blood.
The first human trials of heparin began in May 1935, and, by 1937, it was clear that Connaught's heparin was safe, easily available, and effective as a blood anticoagulant. Before 1933, heparin was available in small amounts, was extremely expensive and toxic, and, as a consequence, of no medical value.
In adaptation to higher tendency of cell death, blind mole rats evolved a mutation in the tumor suppressor protein p53 (which is also used in humans) to prevent cells from undergoing apoptosis. Human cancer patients have similar mutations, and blind mole rats were thought to be more susceptible to cancer because their cells cannot undergo ...